SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Ophthalmic Drug

PUBLISHER: Visiongain | PRODUCT CODE: 2151268

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2151268

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026-2036

PUBLISHED:
PAGES: 369 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5916
PDF (Team License - Up to 6 Users)
USD 7004
PDF (Site License)
USD 8228
PDF (Enterprise License - Includes Free Datasets)
USD 10397.20

Add to Cart

Description

Table of Contents

List of Tables

The global AMD and other retinal diseases drugs market is valued at US$12.46 billion in 2026 and is forecast to reach US$29.47 billion by 2036, at a CAGR of 9.0% over the forecast period, driven by rising AMD prevalence in ageing populations, accelerating adoption of longer-acting anti-VEGF therapies, and expanding investment in next-generation treatment modalities.

Technological Innovation Driving Market Expansion

The retinal diseases market is entering a new phase of innovation as manufacturers increasingly focus on extending treatment durability, improving patient convenience, and expanding therapeutic options beyond conventional anti-VEGF therapies. Recent regulatory approvals, positive long-term clinical data, and rising investment in next-generation retinal therapeutics signal a clear shift toward treatments capable of reducing injection frequency while sustaining long-term visual outcomes.

The competitive landscape has strengthened considerably following the approval of extended-dosing anti-VEGF therapies such as EYLEA HD and encouraging real-world evidence supporting Vabysmo in neovascular retinal diseases. Complement inhibitors have established the first disease-modifying treatment options for geographic atrophy, while continued clinical progress in gene therapies is reinforcing the long-term potential of one-time interventions capable of substantially reducing treatment burden.

Innovation in retinal drug delivery is also creating opportunities for more precise and less invasive treatment. Development activity is focused on suprachoroidal delivery systems, subretinal administration, hydrogel implants, microneedle-enabled ocular delivery, and non-viral gene-delivery platforms designed to improve drug penetration and sustained retinal exposure, supporting more personalised treatment strategies and reducing procedural dependence.

Trade, Policy & Supply Chain Dynamics

  • S. trade tariffs could increase the cost of manufacturing and supplying anti-VEGF agents, complement inhibitors, intravitreal injections, and emerging gene and cell therapies.
  • Higher costs for imported biologic inputs, prefilled syringes, sterile packaging, and specialised cold-chain components may pressure margins, delay product launches, and raise the overall cost of retinal treatment.
  • Established manufacturers are expected to mitigate disruption through inventory reserves, diversified sourcing strategies, and increased domestic production capacity.
  • Smaller biotechnology firms and biosimilar developers could face more pronounced cost pressures and supply chain constraints, potentially affecting competitiveness and slowing market entry.
  • Demand for AMD, diabetic macular oedema, diabetic retinopathy, and retinal vein occlusion therapies is expected to remain resilient, as treatment delays can lead to irreversible vision loss.

Commercial Impact

  • Cost pressure: Tariffs on biologic inputs, sterile manufacturing components, and cold-chain infrastructure are increasing production costs and affecting procurement economics for manufacturers and healthcare providers
  • Supply chain shifts: Companies are diversifying sourcing strategies and expanding domestic manufacturing investment to reduce dependency on imported biologic materials and ocular drug-delivery components
  • Biosimilar dynamics: Tariff-related cost pressure is particularly pronounced for biosimilar developers where pricing competitiveness and development expenditure are critical to market entry and positioning
  • Competitive positioning: Manufacturers with diversified supply networks and established domestic production capacity are better positioned to maintain supply continuity and protect margins

Company Intelligence

The AMD and retinal diseases drugs market is characterised by a mix of large pharmaceutical companies, specialist ophthalmology developers, and biosimilar manufacturers competing across clinical pipeline breadth, treatment durability, and drug-delivery innovation.

Leading companies including Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Novartis, Bayer AG, and Biogen are strengthening their positions through extended-dosing programme development, biosimilar defence strategies, and investment in next-generation complement and gene therapy platforms.

Competition is increasingly defined by:

  • Treatment durability and extended dosing interval capability across anti-VEGF programmes
  • Pipeline breadth across complement inhibition, gene therapy, and sustained-release biologic platforms
  • Biosimilar development and interchangeability credentials in maturing anti-VEGF markets
  • Drug-delivery innovation enabling less invasive and more targeted retinal treatment

This report analyses how competitive positioning is evolving across 17 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • What is the projected size of the AMD and retinal diseases drugs market by 2036?
  • Which segments and regions will drive growth?
  • How will longer-acting therapies, complement inhibitors, and gene therapies reshape the competitive landscape?
  • What is the impact of U.S. trade tariffs on manufacturing costs and biosimilar market entry?
  • Who are the leading companies and how will their positions evolve?

Report Scope and Data Coverage

  • Global AMD and retinal diseases drugs market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across disease indication, route of administration, drug type, treatment type, and end user
  • Regional and national market forecasts across five regions and 17 leading national markets
  • Competitive intelligence on 17 leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

Segmentation Framework

By Disease Indication

  • AMD
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Others

By Route of Administration

  • Intravitreal
  • Others

By Drug Type

  • Branded Drugs (Eylea, Lucentis, Vabysmo, Others)
  • Biosimilar Drugs

By Treatment Type

  • Anti-VEGF Agents
  • Complement Pathway Inhibitors
  • Gene & Cell Therapies
  • Dietary Supplements & Antioxidants
  • Others

By End User

  • Hospitals
  • Ambulatory Surgical Centres
  • Speciality Clinics
  • Diagnostic Imaging Centres
  • Others

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 17 leading companies, including:

  • Astellas Pharma
  • Bayer AG
  • Biocon
  • Biogen
  • Chengdu Kanghong Biotech
  • Hoffmann-La Roche Ltd
  • Formycon AG
  • Intas Pharmaceuticals
  • Kodiak Sciences
  • Novartis AG
  • Ocular Therapeutix
  • Outlook Therapeutics
  • Regeneron Pharmaceuticals
  • Sandoz Group AG
  • STADA Arzneimittel AG
  • Mighty Therapeutics
  • Teva Pharmaceutical Industries

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The AMD and retinal diseases drugs market is evolving rapidly, driven by longer-acting anti-VEGF therapies, first-in-class complement inhibitors, and advancing gene therapy programmes.
  • Organisations that understand these dynamics will be better positioned to capture commercial opportunities, manage pipeline risk, and strengthen competitive positioning.
  • Purchase the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.
Show more
Product Code: PHA1394

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Rising Prevalence of AMD in Ageing Population
      • 3.3.1.2 Accelerating adoption of longer-acting anti-VEGF therapies
      • 3.3.1.3 Improved Ophthalmic Imaging with AI-Enabled Early Detection
      • 3.3.1.4 Increasing Healthcare Expenditure on Vision Preservation
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Stringent Regulatory and Safety Requirements
      • 3.3.2.2 High Cost of Biologics and Gene Therapies
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Unmet Need in Dry AMD and Geography Atrophy Treatment
      • 3.3.3.2 Expansion of Next-Generation Drug Modalities in Retinal Diseases
      • 3.3.3.3 Growing Requirement for Safer and More Durable Retinal Therapies
  • 3.4 U.S. Tariffs: What's the Impact on Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
    • 3.4.3 Why V-Shaped Recovery?
      • 3.4.3.1 Impact from Tariffs
      • 3.4.3.2 Market Dynamics and Demand Recovery
      • 3.4.3.3 Policy and Funding Support
      • 3.4.3.4 Timeframe for Recovery
    • 3.4.4 U-Shaped Recovery Scenario
      • 3.4.4.1 Why U-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 L-Shaped Recovery Scenario
      • 3.4.5.1 Why L-Shaped Recovery?
      • 3.4.5.2 Impact from Tariffs
      • 3.4.5.3 Market Dynamics and Demand Recovery
      • 3.4.5.4 Policy and Funding Support
      • 3.4.5.5 Timeframe for Recovery
    • 3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.7 Impact of U.S. and China Trade War on Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market
    • 3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Impacts As Result from These Policy Changes?
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Supplier Power
    • 3.5.2 Bargaining Power of Buyer
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat from Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis
  • 3.7 Pipeline Analysis

4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Disease Indication

  • 4.1 Key Findings
  • 4.2 Disease Indication Segment: Market Attractiveness Index
  • 4.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
  • 4.4 AMD
  • 4.5 AMD by Type
    • 4.5.1 Dry AMD
    • 4.5.2 Wet AMD
    • 4.5.3 Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
    • 4.5.4 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.5.5 Market Share by Region, 2026 & 2036 (%)
  • 4.6 Diabetic Macular Edema
    • 4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.7 Diabetic Retinopathy
    • 4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.7.2 Market Share by Region, 2026 & 2036 (%)
  • 4.8 Retinal Vein Occlusion
    • 4.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.8.2 Market Share by Region, 2026 & 2036 (%)
  • 4.9 Others
    • 4.9.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 4.9.2 Market Share by Region, 2026 & 2036 (%)

5 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Route of Administration

  • 5.1 Key Findings
  • 5.2 Route of Administration Segment: Market Attractiveness Index
  • 5.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 5.4 Intravitreal
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Others
    • 5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)

6 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Drug Type

  • 6.1 Key Finding
  • 6.2 Drug Type Segment: Market Attractiveness Index
  • 6.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
  • 6.4 Branded Drugs
  • 6.5 Branded Drugs by Type
    • 6.5.1 Eylea
    • 6.5.2 Lucentis
    • 6.5.3 Vabysmo
    • 6.5.4 Others
    • 6.5.5 Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
    • 6.5.6 Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 6.5.7 Market Share by Region, 2026 & 2036 (%)
  • 6.6 Biosimilar Drugs
    • 6.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 6.6.2 Market Share by Region, 2026 & 2036 (%)

7 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Treatment Type

  • 7.1 Key Findings
  • 7.2 Treatment Type Segment: Market Attractiveness Index
  • 7.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
  • 7.4 Anti-VEGF Agents
    • 7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Complement Pathway Inhibitors
    • 7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Gene & Cell Therapies
    • 7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)
  • 7.7 Dietary Supplements and Antioxidants
    • 7.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.7.2 Market Share by Region, 2026 & 2036 (%)
  • 7.8 Others
    • 7.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 7.8.2 Market Share by Region, 2026 & 2036 (%)

8 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by End-users

  • 8.1 Key Findings
  • 8.2 End-users Segment: Market Attractiveness Index
  • 8.3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
  • 8.4 Hospitals
    • 8.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Ambulatory Surgical Centres
    • 8.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Retinal Centres
    • 8.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)
  • 8.7 Diagnostic Imaging Centres
    • 8.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.7.2 Market Share by Region, 2026 & 2036 (%)
  • 8.8 Others
    • 8.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
    • 8.8.2 Market Share by Region, 2026 & 2036 (%)

9 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • 10.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 10.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
  • 10.5 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
  • 10.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 10.7 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
  • 10.8 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
  • 10.9 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
  • 10.10 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 10.11 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

11 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • 11.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 11.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
  • 11.5 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
  • 11.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.7 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
  • 11.8 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
  • 11.9 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
  • 11.10 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 11.11 UK Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 11.12 France Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 11.13 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 11.14 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 11.15 Russia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 11.16 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

12 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • 12.3 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 12.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
  • 12.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.7 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
  • 12.8 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
  • 12.9 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
  • 12.10 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 12.11 China Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 12.12 India Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 12.13 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 12.14 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 12.15 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

13 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • 13.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 13.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
  • 13.5 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
  • 13.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.7 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
  • 13.8 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
  • 13.9 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
  • 13.10 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 13.11 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 13.12 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

14 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • 14.3 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 14.4 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Country
  • 14.5 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Disease Indication
  • 14.6 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Route of Administration
  • 14.7 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Drug Type
  • 14.8 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by Treatment Type
  • 14.9 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Size Estimation and Forecast by End-users
  • 14.10 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 14.11 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis
  • 14.12 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Analysis

15 Company Profiles

  • 15.1 Astellas Pharma
    • 15.1.1 Company Snapshot
    • 15.1.2 Company Overview
    • 15.1.3 Financial Analysis
      • 15.1.3.1 Net Revenue, 2022-2025
      • 15.1.3.2 R&D, 2022-2025
      • 15.1.3.3 Regional Market Shares, 2025
      • 15.1.3.4 Business Segment Market Shares, 2025
    • 15.1.4 Product Benchmarking
    • 15.1.5 Strategic Outlook
  • 15.2 Bayer AG
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Financial Analysis
      • 15.2.3.1 Net Revenue, 2022-2025
      • 15.2.3.2 R&D, 2022-2025
      • 15.2.3.3 Regional Market Shares, 2025
      • 15.2.3.4 Business Segment Market Shares, 2025
    • 15.2.4 Product Benchmarking
    • 15.2.5 Strategic Outlook
  • 15.3 Biocon
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2022-2025
    • 15.3.4 Product Benchmarking
    • 15.3.5 Strategic Outlook
  • 15.4 Biogen
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2022-2025
      • 15.4.3.2 R&D, 2022-2025
      • 15.4.3.3 Regional Market Shares, 2025
      • 15.4.3.4 Business Segment Market Shares, 2025
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Chengdu Kanghong Biotech
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Product Benchmarking
  • 15.6 F. Hoffmann-La Roche Ltd
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2022-2025
      • 15.6.3.2 R&D, 2022-2025
      • 15.6.3.3 Business Segment Market Shares, 2025
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 Formycon AG
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2022-2025
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 Intas Pharmaceuticals
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Product Benchmarking
  • 15.9 Kodiak Sciences
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Strategic Outlook
  • 15.10 Novartis AG
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2022-2025
      • 15.10.3.2 R&D, 2022-2025
      • 15.10.3.3 Regional Market Shares, 2025
      • 15.10.3.4 Business Segment Market Shares, 2025
    • 15.10.4 Product Benchmarking
    • 15.10.5 Strategic Outlook
  • 15.11 Ocular Therapeutix
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2022-2025
    • 15.11.4 Product Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 Outlook Therapeutics
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Product Benchmarking
    • 15.12.4 Strategic Outlook
  • 15.13 Regeneron Pharmaceuticals
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2022-2025
      • 15.13.3.2 R&D, 2022-2025
    • 15.13.4 Product Benchmarking
    • 15.13.5 Strategic Outlook
  • 15.14 Sandoz Group AG
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 Net Revenue, 2022-2025
      • 15.14.3.2 R&D, 2022-2025
    • 15.14.4 Product Benchmarking
    • 15.14.5 Strategic Outlook
  • 15.15 STADA Arzneimittel AG
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2022-2025
    • 15.15.4 Product Benchmarking
    • 15.15.5 Strategic Outlook
  • 15.16 Mighty Therapeutics
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Product Benchmarking
    • 15.16.4 Strategic Outlook
  • 15.17 Teva Pharmaceutical Industries
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Financial Analysis
      • 15.17.3.1 Net Revenue, 2022-2025
      • 15.17.3.2 R&D, 2022-2025
      • 15.17.3.3 Regional Market Shares, 2025
    • 15.17.4 Product Benchmarking
    • 15.17.5 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
Show more
Product Code: PHA1394

List of Tables

  • Table 1 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
  • Table 2 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): V- Shaped Recovery
  • Table 3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): U- Shaped Recovery
  • Table 4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): L-Shaped Recovery
  • Table 5 AMD : Pipeline Drugs ( Phase II & III)
  • Table 6 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 7 AMD Segment Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 8 AMD Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 9 Diabetic Macular Edema Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 10 Diabetic Retinopathy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 11 Retinal Vein Occlusion Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 12 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 13 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 14 Intravitreal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 15 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 16 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 17 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 18 Branded Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 19 Biosimilar Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 20 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 21 Anti-VEGF Agents Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 22 Complement Pathway Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 23 Gene & Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 24 Dietary Supplements and Antioxidants Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 25 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 26 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 27 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 28 Ambulatory Surgical Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 29 Retinal Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 30 Diagnostic Imaging Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 31 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 32 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 33 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 34 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 35 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 36 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 37 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 38 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 39 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 40 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 41 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 42 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 43 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 44 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 45 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 46 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 47 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 48 UK Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 49 France Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 50 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 51 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 52 Russia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 53 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 54 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 55 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 56 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 57 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 58 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 59 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 60 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 61 China Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 62 India Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 63 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 64 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 65 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 66 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 67 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 68 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 69 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 70 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 71 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 72 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 73 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 74 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 75 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 76 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 77 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 78 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 79 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 80 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %, CAGR %)
  • Table 81 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 82 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 83 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US $ Billion, AGR%, CAGR%)
  • Table 84 Astellas Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Astellas Pharma: Product Benchmarking
  • Table 86 Astellas Pharma: Strategic Outlook
  • Table 87 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Bayer AG: Product Benchmarking
  • Table 89 Bayer AG: Strategic Outlook
  • Table 90 Biocon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Biocon: Product Benchmarking
  • Table 92 Biocon: Strategic Outlook
  • Table 93 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Biogen: Product Benchmarking
  • Table 95 Biogen: Strategic Outlook
  • Table 96 Chengdu Kanghong Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Chengdu Kanghong Biotech: Product Benchmarking
  • Table 98 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 100 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 101 Formycon AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Formycon AG: Product Benchmarking
  • Table 103 Formycon AG: Strategic Outlook
  • Table 104 Intas Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Intas Pharmaceuticals: Product Benchmarking
  • Table 106 Kodiak Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 Kodiak Sciences: Product Benchmarking
  • Table 108 Kodiak Sciences: Strategic Outlook
  • Table 109 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 Novartis AG: Product Benchmarking
  • Table 111 Novartis AG: Strategic Outlook
  • Table 112 Ocular Therapeutix: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Ocular Therapeutix: Product Benchmarking
  • Table 114 Ocular Therapeutix: Strategic Outlook
  • Table 115 Outlook Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Outlook Therapeutics: Product Benchmarking
  • Table 117 Outlook Therapeutics: Strategic Outlook
  • Table 118 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119 Regeneron Pharmaceuticals: Product Benchmarking
  • Table 120 Regeneron Pharmaceuticals: Strategic Outlook
  • Table 121 Sandoz Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Sandoz Group AG: Product Benchmarking
  • Table 123 Sandoz Group AG: Strategic Outlook
  • Table 124 STADA Arzneimittel AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 STADA Arzneimittel AG: Product Benchmarking
  • Table 126 STADA Arzneimittel AG: Strategic Outlook
  • Table 127 Mighty Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128 Mighty Therapeutics: Product Benchmarking
  • Table 129 Mighty Therapeutics: Strategic Outlook
  • Table 130 Teva Pharmaceutical Industries: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 Teva Pharmaceutical Industries: Product Benchmarking
  • Table 132 Teva Pharmaceutical Industries: Strategic Outlook

List of Figures

  • Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Segmentation
  • Figure 2 Macular Degeneration (AMD) :: Research Methodology
  • Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Disease Indication : Market Attractiveness Index
  • Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Treatment Type: Market Attractiveness Index
  • Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by End-users: Market Attractiveness Index
  • Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Market Dynamics
  • Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Impact Analysis
  • Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 12 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 13 Short Term & Long-Term Planning
  • Figure 14 Impact of U.S. and China Trade War
  • Figure 15 Most Impacted Countries
  • Figure 16 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Porter's Five Forces Analysis
  • Figure 17 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: PEST Analysis
  • Figure 18 AMD Pipeline by Mechanism of Action (n=12 assets) : Phase II & III
  • Figure 19 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Disease Indication
  • Figure 20 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
  • Figure 21 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication, 2026, 2031, 2036 (%)
  • Figure 22 AMD Segment Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 23 AMD Market Share Forecast by Type, 2026, 2031, 2036 (%)
  • Figure 24 AMD Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 25 AMD Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 26 Diabetic Macular Edema Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 27 Diabetic Macular Edema Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 28 Diabetic Retinopathy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 29 Diabetic Retinopathy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 30 Retinal Vein Occlusion Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 31 Retinal Vein Occlusion Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 32 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 33 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 34 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Disease Indication
  • Figure 35 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 36 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
  • Figure 37 Intravitreal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 38 Intravitreal Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 39 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 40 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 41 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Drug Type
  • Figure 42 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 43 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026, 2031, 2036 (%)
  • Figure 44 Branded Drugs Segment Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 45 Branded Drugs Market Share Forecast by Type, 2026, 2031, 2036 (%)
  • Figure 46 Branded Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 47 Branded Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 48 Branded Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 49 : Aflibercept Biosimilars : Status in U.S.
  • Figure 50 Biosimilar Drugs Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 51 Biosimilar Drugs Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 52 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by Treatment Type
  • Figure 53 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 54 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026, 2031, 2036 (%)
  • Figure 55 Anti-VEGF Agents Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 56 Anti-VEGF Agents Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 57 Complement Pathway Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 58 Complement Pathway Inhibitors Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 59 Gene & Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 60 Gene & Cell Therapies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 61 Dietary Supplements and Antioxidants Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 62 Dietary Supplements and Antioxidants Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 63 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 64 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 65 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index by End-users
  • Figure 66 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 67 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026, 2031, 2036 (%)
  • Figure 68 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 69 Hospitals Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 70 Ambulatory Surgical Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 71 Ambulatory Surgical Centres Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 72 Speciality Clinics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 73 Retinal Centres Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 74 Diagnostic Imaging Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 75 Diagnostic Imaging Centres Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 76 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 77 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 78 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
  • Figure 79 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 80 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026-2036 (US$ Mn)
  • Figure 81 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • Figure 82 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 83 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 84 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 85 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 86 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication, 2026 & 2036 (%)
  • Figure 87 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 88 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 89 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 90 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 91 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 92 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
  • Figure 93 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 94 North America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 95 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 96 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 97 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • Figure 98 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 99 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 100 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 101 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
  • Figure 102 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
  • Figure 103 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 104 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 105 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 106 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 107 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 108 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
  • Figure 109 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 110 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 111 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 112 UK Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 113 France Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 114 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 115 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 116 Russia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 117 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 118 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • Figure 119 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 120 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 121 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 122 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
  • Figure 123 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
  • Figure 124 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 125 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 126 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 127 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 128 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 129 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
  • Figure 130 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 131 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 132 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 133 China Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 134 India Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 135 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 136 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 137 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 138 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • Figure 139 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 140 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 141 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 142 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication , 2026-2036 (US$ Billion, AGR %)
  • Figure 143 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication , 2026 & 2036 (%)
  • Figure 144 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 145 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 146 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 147 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 148 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 149 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
  • Figure 150 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 151 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 152 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 153 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 154 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 155 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Attractiveness Index
  • Figure 156 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 157 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 158 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 159 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Disease Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 160 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Disease Indication, 2026 & 2036 (%)
  • Figure 161 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 162 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 163 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 164 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 165 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by Treatment Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 166 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by Treatment Type, 2026 & 2036 (%)
  • Figure 167 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
  • Figure 168 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 169 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 170 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 171 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 172 Astellas Pharma: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 173 Astellas Pharma: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 174 Astellas Pharma: Regional Market Shares (%), 2025
  • Figure 175 Astellas Pharma: Business Segment Market Shares (%), 2025
  • Figure 176 Bayer AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 177 Bayer AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 178 Bayer AG: Regional Market Shares (%), 2025
  • Figure 179 Bayer AG: Business Segment Market Shares (%), 2025
  • Figure 180 Biocon: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 181 Biogen: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 182 Biogen: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 183 Biogen: Regional Market Shares (%), 2025
  • Figure 184 Biogen: Business Segment Market Shares (%), 2025
  • Figure 185 F. Hoffmann-La Roche Ltd: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 186 F. Hoffmann-La Roche Ltd: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 187 F. Hoffmann-La Roche Ltd: Business Segment Market Shares (%), 2025
  • Figure 188 Formycon AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 189 Novartis AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 190 Novartis AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 191 Novartis AG: Regional Market Shares (%), 2025
  • Figure 192 Novartis AG: Business Segment Market Shares (%), 2025
  • Figure 193 Ocular Therapeutix: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 194 Regeneron Pharmaceuticals: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 195 Regeneron Pharmaceuticals: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 196 Sandoz Group AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 197 Sandoz Group AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 198 STADA Arzneimittel AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 199 Teva Pharmaceutical Industries: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 200 Teva Pharmaceutical Industries: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 201 Teva Pharmaceutical Industries: Regional Market Shares (%), 2025
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!